The combination of adoptive transfer of ex vivo primed MiHA-specific CD8+ T cells with PD-L silenced DCs vaccines targeting hematopoietic-restricted MiHAs would greatly contribute to better GVT immunity without inducing detrimental GVHD. Here, CD8A is linked to graft versus host disease.